Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
Amand F. Schmidt, Daniel I. Swerdlow, Michael V. Holmes, et al.
The Lancet Diabetes & Endocrinology (2016) Vol. 5, Iss. 2, pp. 97-105
Open Access | Times Cited: 353

Showing 1-25 of 353 citing articles:

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
François Mach, Colin Baigent, Alberico L. Catapano, et al.
European Heart Journal (2019) Vol. 41, Iss. 1, pp. 111-188
Open Access | Times Cited: 6803
The MR-Base platform supports systematic causal inference across the human phenome
Gibran Hemani, Jie Zheng, Benjamin Elsworth, et al.
eLife (2018) Vol. 7
Open Access | Times Cited: 5820
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
François Mach, Colin Baigent, Alberico L. Catapano, et al.
Atherosclerosis (2019) Vol. 290, pp. 140-205
Open Access | Times Cited: 4150
Recent Developments in Mendelian Randomization Studies
Jie Zheng, Denis Baird, Maria Carolina Borges, et al.
Current Epidemiology Reports (2017) Vol. 4, Iss. 4, pp. 330-345
Open Access | Times Cited: 864
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality
Michael V. Holmes, Mika Ala‐Korpela, George Davey Smith
Nature Reviews Cardiology (2017) Vol. 14, Iss. 10, pp. 577-590
Open Access | Times Cited: 578
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Paul M. Ridker, James H. Revkin, Pierre Amarenco, et al.
New England Journal of Medicine (2017) Vol. 376, Iss. 16, pp. 1527-1539
Open Access | Times Cited: 569
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Marc S. Sabatine, Lawrence A. Leiter, Stephen D. Wiviott, et al.
The Lancet Diabetes & Endocrinology (2017) Vol. 5, Iss. 12, pp. 941-950
Open Access | Times Cited: 535
Exome-wide association study of plasma lipids in >300,000 individuals
Dajiang J. Liu, Gina M. Peloso, Haojie Yu, et al.
Nature Genetics (2017) Vol. 49, Iss. 12, pp. 1758-1766
Open Access | Times Cited: 515
Genetic drug target validation using Mendelian randomisation
Amand F. Schmidt, Chris Finan, María Gordillo‐Marañón, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 340
Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract
François Mach, Kausik K. Ray, Olov Wiklund, et al.
European Heart Journal (2018) Vol. 39, Iss. 27, pp. 2526-2539
Open Access | Times Cited: 332
Safety and efficacy of statin therapy
Bhavin Adhyaru, Terry A. Jacobson
Nature Reviews Cardiology (2018) Vol. 15, Iss. 12, pp. 757-769
Closed Access | Times Cited: 329
Mendelian randomization for cardiovascular diseases: principles and applications
Susanna C. Larsson, Adam S. Butterworth, Stephen Burgess
European Heart Journal (2023) Vol. 44, Iss. 47, pp. 4913-4924
Open Access | Times Cited: 274
Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease
Wei Zhao, Asif Rasheed, Emmi Tikkanen, et al.
Nature Genetics (2017) Vol. 49, Iss. 10, pp. 1450-1457
Open Access | Times Cited: 260
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Kausik K Ray, Helen M Colhoun, Michael Szarek, et al.
The Lancet Diabetes & Endocrinology (2019) Vol. 7, Iss. 8, pp. 618-628
Open Access | Times Cited: 260
PCSK9
Michael D. Shapiro, Hagai Tavori, Sergio Fazio
Circulation Research (2018) Vol. 122, Iss. 10, pp. 1420-1438
Open Access | Times Cited: 240
The Evolving Future of PCSK9 Inhibitors
Robert S. Rosenson, Robert A. Hegele, Sergio Fazio, et al.
Journal of the American College of Cardiology (2018) Vol. 72, Iss. 3, pp. 314-329
Open Access | Times Cited: 212
Application of magnetic nanoparticles in nucleic acid detection
Congli Tang, Ziyu He, Hongmei Liu, et al.
Journal of Nanobiotechnology (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 199
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Amand F. Schmidt, Lucy S Pearce, John T. Wilkins, et al.
Cochrane library (2017)
Open Access | Times Cited: 179
Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities
Venexia Walker, George Davey Smith, Neil M Davies, et al.
International Journal of Epidemiology (2017) Vol. 46, Iss. 6, pp. 2078-2089
Open Access | Times Cited: 176
Using Mendelian Randomization to Improve the Design of Randomized Trials
Brian A. Ference, Michael V. Holmes, George Davey Smith
Cold Spring Harbor Perspectives in Medicine (2021), pp. a040980-a040980
Open Access | Times Cited: 170
A Mendelian randomization study of the effects of blood lipids on breast cancer risk
Christoph Nowak, Johan Ärnlöv
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 161
PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor
Lorenzo Da Dalt, Massimiliano Ruscica, Fabrizia Bonacina, et al.
European Heart Journal (2018) Vol. 40, Iss. 4, pp. 357-368
Open Access | Times Cited: 160
Lipid-Lowering Agents
Robert A. Hegele, Sotirios Tsimikas
Circulation Research (2019) Vol. 124, Iss. 3, pp. 386-404
Closed Access | Times Cited: 145
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development
Michael V. Holmes, Tom G. Richardson, Brian A. Ference, et al.
Nature Reviews Cardiology (2021) Vol. 18, Iss. 6, pp. 435-453
Open Access | Times Cited: 142
Statistical methods for cis‐Mendelian randomization with two‐sample summary‐level data
Apostolos Gkatzionis, Stephen Burgess, Paul J. Newcombe
Genetic Epidemiology (2022) Vol. 47, Iss. 1, pp. 3-25
Open Access | Times Cited: 79
Page 1 - Next Page

Scroll to top